OPRX - OptimizeRx Q4 results mixed co sees FY 2023 Y/Y revenue growth below consensus
2023-03-08 16:04:23 ET
- OptimizeRx press release ( NASDAQ: OPRX ): Q4 Non-GAAP EPS of $0.25 beats by $0.01 .
- Revenue of $19.7M (-3.0% Y/Y) misses by $2.07M .
- For the full year 2023, the company expects net revenues to increase at least 10% year-over-year. The consensus FY 2023 revenue estimate is for Y/Y growth of 20.5%.
- Sees Q1 2023 revenue to come in between $11.5 million and $13 million. The consensus Q1 2023 revenue estimate is $15.95M.
For further details see:
OptimizeRx Q4 results mixed, co sees FY 2023 Y/Y revenue growth below consensus